Trials / Terminated
TerminatedNCT02786979
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Beraprost | Oral |
| DRUG | Aspirin | Oral |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2016-06-01
- Last updated
- 2016-06-21
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02786979. Inclusion in this directory is not an endorsement.